← Back to Search
A Consensus On Criteria For Cure Of Acromegaly.
A. Giustina, P. Chanson, M. Bronstein, A. Klibanski, S. Lamberts, F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed
Published 2010 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
OBJECTIVE The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on criteria for cure as defined in 2000. PARTICIPANTS Participants included 74 neurosurgeons and endocrinologists with extensive experience of treating acromegaly. EVIDENCE/CONSENSUS PROCESS: Relevant assays, biochemical measures, clinical outcomes, and definition of disease control were discussed, based on the available published evidence, and the strength of consensus statements was rated. CONCLUSIONS Criteria to define active acromegaly and disease control were agreed, and several significant changes were made to the 2000 guidelines. Appropriate methods of measuring and achieving disease control were summarized.
This paper references
Aortic stiffness is increased in acromegaly--a transthoracic echocardiographic study.
A. Nemes (2008)
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps.
P. Maisonneuve (2008)
Diagnostic value of the acidlabile subunit in acromegaly : evaluation in comparison with insulin - like growth factor ( IGF ) I , and IGFbinding protein1 ,2 , and - 3
M Arosio (2001)
Risk factors for development of coro3146 Giustina et al
V DiBello (2007)
Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study.
R. Attanasio (2008)
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
G. Guyatt (2008)
Clinical and biochemical improvement in acromegaly during pregnancy
S. L. Lau (2008)
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly
A. Colao (2006)
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
J. Ayuk (2004)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
P. Rainer (2000)
The First International Standard For Insulin-like Growth Factor-1 (IGF-1) for immunoassay: preparation and calibration in an international collaborative study.
C. Burns (2009)
Determinants of clinical outcome and survival in acromegaly
C. Rajasoorya (1994)
Diagnosis and treatment of acromegaly complications
A. Giustina (2003)
Estroprogestinic pill normalizes IGF-I levels in acromegalic women
R. Cozzi (2003)
Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index.
A. M. Arafat (2008)
Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
M. Arosio (2001)
Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
A. Bianchi (2009)
Prevalence of vertebral fractures in men with acromegaly.
G. Mazziotti (2008)
Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.
E. Van Cutsem (2007)
S,ZibK,BennettWF,DavisRJ2000Treatmentofacromegalywiththe growth hormone-receptor antagonist pegvisomant
PJ Trainer (2000)
Serum Insulin-Like Growth Factor I Reference Values for an Automated Chemiluminescence Immunoassay System: Results from a Multicenter Study
G. Brabant (2003)
The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'.
P. Nomikos (2005)
Guidelines for acromegaly management.
S. Melmed (2002)
Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates.
M. Losa (2006)
Serum levels of insulin-like growth factor I and its binding proteins in health and disease.
A. Juul (2003)
Increased prevalence of regurgitant valvular heart disease in acromegaly.
A. Pereira (2004)
Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.
A. Giustina (1998)
Insulin resistance and insulin secretion in non-diabetic acromegalic patients.
M. Coculescu (2007)
Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly.
K. Morrison (2007)
Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.
S. Orme (1998)
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
A. Colao (2006)
AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects.
M. Bex (2007)
Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly.
J. Puder (2005)
Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.
R. D. Murray (2004)
The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
J. Carmichael (2009)
Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
P. Freda (1998)
Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study
S. Orme (1998)
Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
G. Kaltsas (2001)
Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study.
F. Bogazzi (2007)
Resistance to somatostatin analogs in acromegaly: An evolving concept?
M. Gola (2006)
Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
W. Elliott (2009)
Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.
P. De (2003)
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system
F. Minuto (2004)
Octreotide as primary therapy for acromegaly.
C. Newman (1998)
A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
S. Melmed (2005)
Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study
U. Plöckinger (2005)
Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly.
O. Alexopoulou (2008)
Monitoring of acromegaly: what should be performed when GH and IGF‐1 levels are discrepant?
P. Freda (2009)
Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults
A. Giustina (2008)
Attenuated pulse size, disorderly growth hormone and prolactin secretion with preserved nyctohemeral rhythm distinguish irradiated from surgically treated acromegaly patients
A. A. van der Klaauw (2007)
Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays.
C. Massart (2006)
Transsphenoidal Surgery for Acromegaly: Endocrinological Follow-up of 98 Patients
I. Shimon (2001)
Medical progress: Acromegaly.
S. Melmed (2006)
Guidelines for acromegaly management: an update.
S. Melmed (2009)
Effects of preoperative octreotide treat
T Abe (2001)
Value of insulin-like growth factor system markers in the assessment of growth hormone status.
D. Clemmons (2007)
Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.
T. Abe (2001)
Gender and age influence the relationship between serum GH and IGF‐I in patients with acromegaly
C. Parkinson (2002)
Screening guidelines for colorectal cancer and polyps in patients with acromegaly
P. Jenkins (2002)
Total and free insulin-like growth factor I, insulin-like growth factor binding protein 3 and acid-labile subunit reflect clinical activity in acromegaly.
S. B. Sneppen (2001)
Modulation of growth hormone action by sex steroids
U. Meinhardt (2006)
Consensus statement on the standardisation of GH assays.
P. Trainer (2006)
Characterization of 24‐hour growth hormone secretion in acromegaly: implications for diagnosis and therapy
K. L. Ho (1994)
Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
R. Feelders (2005)
Consensus statement: medical management of acromegaly.
S. Melmed (2005)
Long-term treatment outcome in acromegaly.
I. Holdaway (2003)
Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
P. Petrossians (2005)
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
M. Mercado (2007)
Does partial surgical tumour removal influence the response to octreotide‐LAR in acromegalic patients previously resistant to the somatostatin analogue?
R. Jallad (2007)
Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi‐Society Task Force on Colorectal Cancer, and the American College of Radiology * †
B. Levin (2008)
Risk factors for development of coro 3146 Giustina et al. Criteria for Cure of Acromegaly
F Bogazzi (2007)
Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial.
S. Carlsen (2008)
Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months.
A. Colao (2008)
Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide
W. Ludlam (2008)
Transsphenoidal Microsurgery for Newly Diagnosed Acromegaly: A Personal View after More than 1,000 Operations
Dieter K. Lüdecke (2006)
Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
R. Baldelli (2000)
A highly sensitive growth hormone (GH) enzyme-linked immunosorbent assay uncovers increased contribution of a tonic mode of GH secretion in adults with organic GH deficiency.
A. T. Reutens (1996)
Criteria for cure of acromegaly: a consensus statement.
A. Giustina (2000)
Variation in GH and IGF‐I assays limits the applicability of international consensus criteria to local practice
A. Pokrajac (2007)
Effect of gender and gonadal status on the long‐term response to somatostatin analogue treatment in acromegaly
A. Colao (2005)
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.
I. Holdaway (2008)
Effect of octreotide pretreatment on surgical outcome in acromegaly.
A. Colao (1997)
Factors influencing mortality in acromegaly.
I. Holdaway (2004)
Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly
C. Beauregard (2003)
Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa
J. C. Maiza (2007)
Total and free
SB Sneppen (2001)
Effect of Octreotide, a Somatostatin Analog, on Sleep Apnea in Patients with Acromegaly
R. Grunstein (1994)
Asia Pacific consensus recommendations for colorectal cancer screening
J. Sung (2008)
Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
P. Marzullo (2001)
Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels.
A. Barkan (2003)
Treatmentofacromegalywiththe growth hormonereceptor antagonist pegvisomant
PJ Trainer (2000)
Use of the oral glucose tolerance test to define remission in acromegaly.
H. Vierhapper (2003)
Significant tumour shrinkage after 12 months of lanreotide Autogel‐120 mg treatment given first‐line in acromegaly
A. Colao (2009)
Problems with GH assays and strategies toward standardization.
M. Bidlingmaier (2008)
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
R. Cozzi (2006)
Mortality in acromegaly: a metaanalysis.
O. Dekkers (2008)
Increased Prevalence of Radiological Spinal Deformities in Active Acromegaly: A Cross‐Sectional Study in Postmenopausal Women
S. Bonadonna (2005)
Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: An open-label, multicenter, non-comparative study
S. Grottoli (2005)
Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly.
A. Ben-Shlomo (2003)
Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
E. Dimaraki (2002)
Identification of acromegalic patients at risk of developing colonic adenomas.
F. Bogazzi (2006)
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
A. Colao (2006)
Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
O. Serri (2004)
Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease.
M. Davi’ (2008)
Long‐term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly
G. Amato (2002)
Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status
A. Espinosa-de-los-Monteros (2006)
Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements.
N. Biermasz (2004)
This paper is referenced by
MANEJO DE PACIENTES CON ACROMEGALIA.
Marcos Lima-Martínez (2013)
Are We Achieving Pharmacological Disease Control in Acromegaly
Annamaria Colao (2010)
Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly
M. Baroni (2015)
What is the effect of peripheral muscle fatigue, pulmonary function, and body composition on functional exercise capacity in acromegalic patients?
A. J. Lopes (2015)
Chapter 21 – Physiological and Pathophysiological Alterations of the Neuroendocrine Components of the Reproductive Axis
R. Nass (2014)
Cystatin‐C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly
A. Aulinas (2017)
Measurement of basal GH in the diagnosis of acromegaly.
P. Rosário (2010)
Functional changes are associated with tracheal structural abnormalities in patients with acromegaly
G. Camilo (2016)
Long-term follow-up results of multimodal treatment with initial surgical approach for acromegaly in a single center
K. Rompaey (2012)
YEARS OF NEUROENDOCRINOLOGY Acromegaly
C. Capatina (2015)
Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity.
P. Kamenický (2011)
Intraoperative magnetic resonance imaging during surgery for pituitary adenomas: pros and cons
M. Buchfelder (2012)
[The OASIS study: therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies].
Manuel Luque-Ramírez (2011)
Management options for persistent postoperative acromegaly.
N. Mathioudakis (2012)
Role of growth hormone signaling pathways in the development of atherosclerosis.
Mayumi Ishikawa (2020)
Impacto dos distúrbios respiratórios do sono em pacientes com acromegalia
São Paulo. (2012)
Growth Hormone–Secreting Tumors
Carrie R. Muh (2012)
[Treatment of acromegaly: a critical analysis of the last ten years].
P. Chanson (2012)
Transsphenoidal surgery for pituitary adenoma: indications and outcomes
T. Dusek (2012)
A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification.
H. Schneider (2011)
[Drug therapy for acromegaly].
M. Góth (2013)
Lanreotide Autogel®: A Review of its Use in the Treatment of Patients with Acromegaly
C. Burness (2014)
Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis.
G. Mazziotti (2015)
Multiple facets in the control of acromegaly
L. Vilar (2013)
Childhood Onset Pituitary Adenoma: Clinical Presentations and Outcomes of 24 Cases
H. Y. Kim (2012)
Clinical implications of growth hormone–secreting tumor subtypes
Katja Kiseljak-Vassiliades (2012)
The impact of sleep apnea treatment on carbohydrate metabolism in patients with acromegaly
Felipe Gaia Duarte (2012)
Growth hormone and Klotho.
C. Schmid (2013)
Biological and radiological exploration and management of non-functioning pituitary adenoma.
G. Raverot (2015)
Limited utility of oral glucose tolerance test in biochemically active acromegaly.
A. Ribeiro-Oliveira (2011)
Overview on the Anatomical and Clinical Aspects of Mandibular Prognathism
Ahmed M. S. Hegazy (2015)
Auditory changes in acromegaly
S. Tabur (2016)See more